Your browser doesn't support javascript.
Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant?
Le infezioni in medicina ; 28(suppl 1):52-56, 2020.
Article | WHO COVID | ID: covidwho-599177
In spite of many ongoing attempts to repurpose existing antivirals, no drugs have emerged yet with the desirable activity against SARS-CoV-2 Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19 Pathogenetic studies have shown significant differences between commonly defined viral pneumonia and COVID-19 pulmonary disease In severe forms, immune/inflammatory alterations reminiscent of disease forms like Macrophage Activation Syndrome (MAS) have been described, and therapeutic options other than anti-infective have been proposed and implemented, such as anti-inflammatory and anticoagulative agents The thrombotic phenomena described in the pulmonary vascular bed of patients with severe COVID-19 suggest the administration of low-molecular weight heparin (LMWH) as standard measure in hospitalized patients with COVID-19





Search on Google
Database: WHO COVID Type: Article Journal: Le infezioni in medicina Year: 2020